Because anti-IL-1β/IL-6 strategies have therapeutic potential for human diseases (e.g., autoimmune and autoinflammatory conditions, as well as coronavirus disease 2019-related sepsis), p62 ligands should be developed as therapeutic agents for a variety of immune-related diseases, particularly systemic inflammation. This evidence concerns the gene IL6 and Sepsis.